---
schema_version: "secwatch.filing_event.v1"
accession: "0001420800-25-000038"
form_type: "8-K"
ticker: "ENOV"
cik: "0001420800"
company_name: "Enovis CORP"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:35:06.536099+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Enovis Q3 sales up 9% to $549M; raises FY adjusted EBITDA and EPS guidance

## Summary
- Q3 net sales $549M (+9% reported, +7% organic); Recon +12% reported, P&R +6% reported.
- Net loss $571M including $548M non-cash goodwill impairment; adjusted EPS $0.75.
- Divested Dr. Comfort (Diabetic Footcare) unit in Oct for up to $60M.
- Raised FY2025 guidance: revenue $2.24-2.27B, adj. EBITDA $395-405M, adj. EPS $3.10-3.25.

## SEC filing metadata
- accession: 0001420800-25-000038
- form_type: 8-K
- ticker: ENOV
- cik: 0001420800
- company_name: Enovis CORP
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420800/000142080025000038/0001420800-25-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420800/000142080025000038/cfx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420800-25-000038
- JSON: https://secwatch.observer/filing/0001420800-25-000038.json
- Plain text: https://secwatch.observer/filing/0001420800-25-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.